Editas Medicine, Inc. $108.6 Million Initial Public Offering
2/8/2016

Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $108.6 million initial public offering of 6,785,000 shares of common stock of Editas Medicine, Inc., which included 885,000 shares from the full exercise of the underwriters’ over-allotment option. The common stock is listed on the NASDAQ Global Select Market under the symbol “EDIT.”

Based in Cambridge, Massachusetts, Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Deanna L. Kirkpatrick, counsel Marcel Fausten and associate Cameron Lewis. The intellectual property and technology team included counsel David R. Bauer and associate Bonnie Chen. Counsel Marcie A. Goldstein provided FINRA advice. The tax team included partner Po Sit and associate Caroline E. Dayton. All members of the Davis Polk team are based in the New York office.